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Introduction
According to the recent data, hepatitis C virus 
(HCV) infection is estimated in about 3.2 million of the 
European Union inhabitants, and 200 000 are from Po-
land [1, 2]. Hepatocyte damage due to HCV infection 
stimulates liver fibrosis resulting in liver cirrhosis (LC) 
and can also be responsible for the development of 
hepatocellular carcinoma (HCC) [3-5]. Since no anti- 
HCV vaccine is available, the reduction of worldwide 
prevalence of HCV infection, as well as prevention 
of advanced liver disease in chronic hepatitis C (CHC) 
patients, can be achieved with an efficient antiviral 
therapy [6]. 
Until 2013 in Poland the only therapeutic option was 
treatment with pegylated interferon alfa (Peg-IFNα) 
and ribavirin (RBV). The sustained virologic response 
(SVR) rate of this regimen was about 40% in patients 
infected with the most prevalent HCV genotype (G) 1 
and up to 70% in G2 or G3 infections [7-9]. In addi-
tion to insufficient efficacy, this regimen was limited 
by numerous adverse events leading to the treatment 
discontinuation and its failure. In 2011, the first gener-
ation of direct-acting antivirals (DAA), protease inhib-
itors boceprevir (BOC) and telaprevir (TVR), became 
registered in the European Union, and finally in 2013 
it was reimbursed in a limited proportion of patients 
in Poland. Addition of these medicines to Peg-IFN and 
RBV improved SVR rates in G1 infected patients up 
to about 70%, but was not applicable for other geno-
types [10]. Unfortunately, these regimens were still 
inefficient in non-responders to the Peg-IFN + RBV 
therapy, cirrhotics, and patients with IL28B genotype 
TT. It even worsened the safety profile compared to 
the Peg-IFN + RBV regimen, particularly in patients 
with advanced liver fibrosis [11]. 
New generation DAA, simeprevir (SMV), sofosbu-
vir (SOF), daclatasvir (DCV) as well as coformulated 
IFN-free regimens of SOF and ledipasvir (SOF/LDV) 
and ombitasvir/paritaprevir boosted with ritonavir 
combined with dasabuvir (OBV/PTV/r + DSV ± RBV) 
became available in Europe from 2014 and reimbursed 
in Poland in mid 2015. They are not only protease, but 
also polymerase and NS5A inhibitors and can be com-
bined with each other to improve efficacy above 90% 
irrespectively of fibrosis, treatment history or host fac-
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tors. The safety profile in the majority of patients is ex-
cellent, and the treatment usually does not exceed 12 
weeks [5, 12-15]. 
The aim of the study was to analyze the efficacy 
achieved with very different regimens for treatment of 
CHC patients in Poland between 2013 and 2016, so at 
the age of significant changes in available therapeutic 
options. 
Material and methods
Data were collected with an Excel (Microsoft) 
based questionnaire filled in by 29 Polish centers from 
15 voivodships involved in diagnosis and treatment of 
HCV-infected patients. All voivodships, except opol-
skie, were included in the database. The questionnaire 
contained information on the number of patients with 
efficacy data available between 1 January 2013 and 31 
March 2016. Efficacy was determined by SVR defined 
by undetectable HCV RNA after at least 12 weeks of 
post-treatment follow-up. Submitted data were com-
bined and efficacy was analyzed with respect to HCV 
genotypes and the administered therapeutic regimen.
Results
As demonstrated in Table 1, a total of 6786 patients 
were included in the database. The large majority were 
infected with G1b (55.7%), followed by G1 without 
available subgenotyping (25.6%) and G3 (13.2%). Based 
on the proportion of G1b among patients with avail-
able subgenotyping, estimated prevalence of G1b in the 
studied population was calculated as 80.6%. 
The sustained virologic response rate for all enrolled 
patients was 56%. The lowest SVR was for mixed geno-
types (13%) and the highest for G2 (92%), but the num-
ber of patients in these two populations was very low and 
they were treated mostly with Peg-IFN + RBV (Table 1). 
Among patients infected with G1, the highest SVR was 
observed for G1a (62%). Despite the estimated high 
proportion of G1b among unidentified G1 patients, the 
SVR rate of 51% was lower compared to patients iden-
tified as G1b infected (56%). As shown in Table 1, SVR 
rates for G3 and G4 were 67% and 56% respectively.
Since 71% (n = 4832) of patients included in the da-
tabase were treated with Peg-IFN + RBV, SVR rates for 
particular genotypes in patients treated with this regi-
men were usually lower compared to general data. How-
ever, once again the highest efficacy was demonstrated 
for G2 and G3, but the SVR rate for G1b was almost 
equal to G1 infected without subgenotyping (Fig. 1).
Treatment efficacy of different regimens in the large 
number of 5646 patients infected with genotype 1 is 
demonstrated in Figure 2. A unique group of 70 pa-
tients treated with natural interferon alfa (natural IFN) 
achieved an extremely low SVR rate of 7%. The re gimen 
with Peg-IFN + RBV, which was standard for many 
years, provided therapeutic success in 50% of them. Rel-
atively low SVR of 47-64% was achieved with the IFN-
based triple regimens containing the first generation 
DAA – BOC or TVR (Fig. 2). Efficacy achieved with the 
second wave DAA (SMV or SOF) but still IFN-based 
regimens was about 70%. Significant improvement with 
an SVR rate exceeding 80% was achieved with IFN-
free therapeutic options, and the highest SVR rate of 
98% was observed in patients treated with OBV/PTV/r 
+ DSV ± RBV (Fig. 2). 
Table 1. Distribution of genotypes and efficacy (SVR) among 6786 patients 
with available efficacy data treated between 1 January 2013 and 31 March 2016 
in 29 Polish centers












1a 126 1.9 78 62
1b 3783 55.7 2105 56
1* 1740 25.6 895 51
2 13 0.2 12 92
3 896 13.2 601 67
4 220 3.2 123 56
5 0 0 0 0
6 0 0 0 0
Mixed 8 0.1 1 13
6786 100 3815 56
*Subgenotyping not available
*Subgenotyping not available
Fig. 1. Sustained virologic response rate after treatment with Peg-IFN + RBV in 
4832 patients infected with different HCV genotypes, between 1 January 2013 












 G1a G1b G1* G2 G3 G4
 n = 93 n = 2365 n = 1321 n = 12 n = 848 n = 193
[%
]
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Efficacy of particular regimens in 1129 patients in-
fected with genotypes 2, 3 and 4 is shown in Table 2. 
The large majority of patients infected with G3 and G4 
received Peg-IFN + RBV; therefore overall efficacy was 
67% and 56% respectively. However, different IFN-free 
therapeutic options were administered in 18 G3/G4 
patients, and all of them achieved an SVR. Sofosbuvir 
+ Peg-IFN + RBV is currently the most popular regi-
men in Poland for treatment of G3 infected patients. In 
the analyzed period it was administered to 33 patients, 
with an SVR rate of 94%. Similar efficacy of 92% was 
achieved among 13 patients infected with G2 treated 
with Peg-IFNα or non-Peg-IFNα and RBV without 
any DAA. Interestingly, there were documented 6 cas-
es of triple IFN-based therapy containing SMV in G4 
infected patients, which failed in all except one patient 
(Table 2). 
Discussion
Lower SVR in undetermined G1 compared to G1b 
patients was due to the different regimens adminis-
tered. Subgenotyping was not obligatory before avail-














 Natural IFN Peg-IFN BOC TVR SMV SOF SOF SOF + SMV OBV/PTV/r SOF/LDV
 + RBV + RBV + Peg-IFN + Peg-IFN + Peg-IFN + Peg-IFN + RBV ± RBV + DSV ± RBV ± RBV
   + RBV + RBV + RBV + RBV
 n = 70 n = 3779 n = 485 n = 805 n = 132 n = 23 n = 7 n = 53 n = 227 n = 64
[%
]
Fig. 2. Sustained virologic response rates achieved after treatment with different regimens in 5646 patients infected with HCV genotype 1, between 1 January 2013 
and 31 March 2016 in 29 Polish centers
Table 2. Sustained virologic response rates achieved after treatment with different regimens in 1129 patients infected with HCV genotypes 2, 3 and 4, between 
1 January 2013 and 31 March 2016 in 29 Polish centers
Genotype 2 Genotype 3 Genotype 4
n SVR n SVR n SVR
Natural IFN + RBV – – 11 0% 1 0%
IFN + RBV 1 100% – – – –
Peg-IFN – – – – 2 0%
Peg-IFN + RBV 12 92% 848 67% 193 55%
TVR + Peg-IFN + RBV – – – – 1 100%
SMV + Peg-IFN + RBV – – – – 6 17%
SOF + Peg-IFN + RBV – – 33 94% 3 33%
OBV/PTV/r ± RBV – – – – 12 100%
SOF/LDV ± RBV – – 1 100% 2 100%
SOF + DCV + RBV – – 1 100% – –
SOF + RBV – – 2 100% – –
Overall 13 92% 896 67% 220 56%
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all patients not subgenotyped for G1 were treated be-
fore mid 2015 with less efficient interferon-based ther-
apeutic options. This explanation was supported by 
similar response rates (49% vs. 51%) in patients treated 
with Peg-IFN + RBV. However, it should be taken into 
consideration that efficacy of IFN-based therapies can 
be affected by numerous other factors including histo-
ry of previous treatment, IL28B genotype and stage of 
the disease, which were not analyzed in our study. 
Figure 2 provides unique information on the natural 
IFN + RBV regimen which was still administered be-
tween 2013 and 2016 to 70 patients. According to our 
knowledge, this old-fashioned therapy was adminis-
tered mostly to patients with strong contraindications to 
Peg-IFN, usually in treatment of patients with advanced 
fibrosis. However, an SVR rate of 7% even in a very dif-
ficult to treat population is insufficient to support use of 
this regimen in the era of IFN-based therapy.
Our data confirmed similar response rates for G1 
and G4 in a large number of patients. We observed 
a relatively low SVR for G3 (67%). According to the lit-
erature, it was expected at the level of 70-80% [7]. In 
contrast, the SVR rate among 13 identified G2 patients 
reached 92%, which was higher than expected, but the 
value of this finding is limited due to the low number 
of patients.
The lower than expected SVR rate achieved with the 
triple regimens containing the first generation DAA, 
particularly BOC, can be explained by the extreme-
ly difficult to treat population of cirrhotics and non-
respon ders to Peg-IFN + RBV enrolled in these regi-
mens. Similar efficacy data were previously reported in 
real world studies such as CUPIC and ADVEX [10, 11]. 
There was a limited number of patients with avail-
able efficacy data after interferon-free regimens. They 
were treated mostly with medication provided as an 
“early access” by pharmaceutical companies in 2014 and 
2015, and the majority of these patients were includ-
ed in the real world studies AMBER and HARVEST. 
Therefore it is not surprising that SVR rates of OBV/
PTV/r + DSV ± RBV and SOF/LDV for G1 infected 
patients are similar to those already reported [14, 15]. 
They are also similar to available real world data from 
other countries and confirm the superiority of the two 
mentioned regimens compared to the combination of 
SOF + SMV ± RBV or SOF + RBV in the G1 popula-
tion [16, 17]. 
A large majority of patients infected with other than 
G1 genotypes were treated with the Peg-IFN + RBV 
regimen (n = 1053). Sofosbuvir + Peg-IFN + RBV treat-
ment was administered to 33 patients infected with G3, 
with 94% efficacy, which is similar to that demonstrated 
in the BOSON study and supports the rationale for cur-
rent recommendations of the Polish HCV Expert Group 
for G3 management [18, 19]. Also worth mentioning 
was a group of 12 patients infected with G4 treated with 
OBV/PTV/r ± RBV, which achieved a 100% response 
rate, similar to that observed in clinical trials and real 
world experience [15, 20]. Altogether, 18 patients in-
fected with G3 or G4 were treated with different inter-
feron-free regimens, and all of them cleared the virus. 
Of course, the numbers are not meaningful, but such 
high efficacy indicates a tendency we should expect in 
the future study containing many more patients treated 
without interferon.
In this study we observed significant differences in 
efficacy of HCV therapeutic options available in Poland 
between 2013 and 2016, at the turn of the interferon 
age. It was probably the last moment we were able to 
collect a large number of patients treated with inter-
feron-based regimens, and therefore these data will be 
useful as a comparison for interferon-free regimens 
which are already available and those expected in the 
next few years. 
Disclosure
Authors report no conflict of interest.
References
1. Razavi H, Robbins S, Zeuzem S, et al. Achieving the WHO Tar-
gets in the European Union. Lancet Gastro Hep 2016 [In press].
2. Flisiak R, Halota W, Horban A, et al. Prevalence and risk factors 
of HCV infection in Poland. Eur J Gastroenterol Hepatol 2011; 
23: 1213-1217.
3. Hatzakis A, Chulanov V, Gadano AC, et al. The present and fu-
ture disease burden of hepatitis C virus (HCV) infections with 
today’s treatment paradigm – volume 2. J Viral Hepat 2015; 
22 (Suppl 1): 26-45.
4. Parkin DM. The global health burden of infection-associated 
cancers in the year 2002. Int J Cancer 2006; 118: 3030-3044.
5. Jaroszewicz J, Flisiak-Jackiewicz M, Lebensztejn D, et al. Cur-
rent drugs in early development for treating hepatitis C virus- 
related hepatic fibrosis. Expert Opin Investig Drugs 2015; 24: 
1229-1239.
6. Flisiak R, Halota W, Tomasiewicz K, et al. Forecasting the dis-
ease burden of chronic hepatitis C virus in Poland. Eur J Gastro-
enterol Hepatol 2015; 27: 70-76.
7. Zeuzem S. Interferon-based therapy for chronic hepatitis C: cur-
rent and future perspectives. Nat Clin Pract Gastroenterol Hepa-
tol 2008; 5: 610-622.
8. Juszczyk J, Białkowska J, Bolewska B, et al. Pegylowany inter-
feronalfa-2b z rybawiryną w leczeniu przewlekłego wirusowego 
zapalenia wątroby typu C. Pol Merk Lek 2004; 16: 353-357.
9. Juszczyk J, Baka-Ćwierz B, Beniowski M, et al. Pegylowany inter-
feron alfa-2a z rybawiryną w leczeniu przewlekłego wirusowego 
zapalenia wątroby typu C. Przeg Epidemiol 2005; 59: 651-660.
10. Janczewska E, Flisiak R, Zarebska-Michaluk D, et al. Effect of 
Peginterferon or Ribavirin Dosing on Efficacy of Therapy With 
Tela previr in Treatment-Experienced Patients With Chronic 
Clinical and Experimental Hepatology 4/2016
Efficacy of HCV treatment in Poland at the turn ofthe interferon era – the EpiTer study 
143
Hepa titis C and Advanced Liver Fibrosis: A Multicenter Cohort 
Study. Medicine 2015; 94: e1411.
11. Hézode C, Fontaine H, Dorival C, et al. Triple therapy in treat-
ment-experienced patients with HCV-cirrhosis in a multi-
centre cohort of the French Early Access Programme (ANRS 
CO20-CUPIC) – NCT01514890. J Hepatol 2013; 59: 434-441.
12. Flisiak R, Jaroszewicz J, Parfieniuk-Kowerda A. Emerging 
treatments for hepatitis C. Expert Opin Emerg Drugs 2013; 18: 
461-475.
13. Jaroszewicz J, Flisiak R, Dusheiko G. A pill for HCV – myth or 
foreseeable future? Liver Int 2014; 34: 6-11.
14. Flisiak R, Łucejko M, Mazur W, et al. Efficacy and safety of 
sofosbuvir/ledipasvir ± ribavirin in the real-world HARVEST 
study. Clin Exp Hep 2016; 2: 80.
15. Flisiak R, Janczewska E, Wawrzynowicz-Syczewska M, et al. 
Real-world effectiveness and safety of Ombitasvir/Paritaprevir/
Ritonavir±Dasabuvir±Ribavirin in hepatitis C: AMBER study. 
Aliment Pharmacol Ther 2016; 44: 946-956.
16. Wang G. Prevalence and impact of baseline resistance-associ-
ated variants (ravs) on the efficacy of Ledipasvir/Sofosbuvir or 
Simeprevir/Sofosbuvir against gt1 HCV infection: HCV-target 
interim analysis. J Hepatol 2016; 64 (Suppl 2): PS-102.
17. Mauss S, Buggisch P, Böker KHW, et al. Treatment outcomes 
for hepatitis C genotype 1 infection with direct acting antivirals: 
data from the German hepatitis C-registry. J Hepatol 2016; 64 
(Suppl 2): SAT-263. 
18. Foster GR, Pianko S, Brown A, et al. Efficacy of sofosbuvir plus 
ribavirin with or without peginterferon-alfa in patients with 
hepatitis C virus genotype 3 infection and treatment-experi-
enced patients with cirrhosis and hepatitis C virus genotype 2 
infection. Gastroenterology 2015; 149: 1462-1470.
19. Halota W, Flisiak R, Boroń-Kaczmarska A, et al. Recommenda-
tions for the treatment of hepatitis C issued by the Polish Group 
of HCV Experts – 2016. Clin Exp Hepatol 2016; 2: 27-33.
20. Hézode C, Asselah T, Reddy KR, et al. Ombitasvir plus pari-
taprevir plus ritonavir with or without ribavirin in treatment- 
naive and treatment experienced patients with genotype 4 chron-
ic hepatitis C virus infection (PEARL-I): a randomised, open- 
label trial. Lancet 2015; 385: 2502-2509.
